You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

CHK1/2 Inhibitor

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Brain Tumor, Brain Tumor, Recurrent, Brain Tumor, Refractory Trial in Memphis (Prexasertib, Cyclophosphamide, Gemcitabine)

Active, not recruiting
  • Brain Tumor
  • +12 more
  • Memphis, Tennessee
    St. Jude Children's Research Hospital
Oct 20, 2022

NSCLC, Non-Small Cell Lung Adenocarcinoma, Non-Small Cell Squamous Lung Cancer Trial in Grand Rapids, San Antonio, Fairfax

Recruiting
  • Non-small Cell Lung Cancer
  • +10 more
  • Grand Rapids, Michigan
  • +2 more
Apr 25, 2023

Advanced Solid Tumors or Non-Hodgkin's Lymphoma (NHL) Trial in United Kingdom (SRA737)

Completed
Has Results
  • Advanced Solid Tumors or Non-Hodgkin's Lymphoma (NHL)
  • Sutton, London, United Kingdom
  • +14 more
Mar 9, 2022

Advanced Cancers Trial in Boston (LY2606368)

Active, not recruiting
Has Results
  • Advanced Cancers
  • Boston, Massachusetts
    Dana Farber Cancer Institute
Jan 18, 2022

Cancer Trial in Boston (LY3300054, Prexasertib)

Completed
  • Cancer
  • Boston, Massachusetts
    Dana Farber Cancer Institute
Apr 13, 2021

Ewing Sarcoma, Ewing-Like Sarcoma Trial in New York (LY2880070, Gemcitabine)

Recruiting
  • Ewing Sarcoma
  • Ewing-Like Sarcoma
  • New York, New York
    Memorial Sloan Kettering Cancer Center (All Protocol Activities)
Aug 18, 2022

Childhood Solid Tumor, Recurrent Malignant Solid Tumor, Recurrent Primary CNS Tumor Trial in United States (Laboratory Biomarker

Completed
  • Childhood Solid Neoplasm
  • +4 more
  • Laboratory Biomarker Analysis
  • +2 more
  • Birmingham, Alabama
  • +20 more
Apr 12, 2021

Metastatic Colorectal Cancer Trial (LB-100, Azenosertib)

Not yet recruiting
  • Metastatic Colorectal Cancer
  • (no location specified)
Oct 31, 2023

Metastatic Microsatellite-stable Colorectal Cancer Trial (LB-100, Atezolizumab)

Not yet recruiting
  • Metastatic Microsatellite-stable Colorectal Cancer
  • (no location specified)
Sep 1, 2023

Solid Tumor Trial in Boston (Prexasertib, Olaparib)

Completed
  • Solid Tumor
  • Boston, Massachusetts
    Dana Farber Cancer Institute
Sep 1, 2021

Advanced Solid Tumor, Refractory Tumor Trial in Suzhou (Radiotherapy, PD-1/PD-L1 inhibitor, Granulocyte-macrophage

Recruiting
  • Advanced Solid Tumor
  • Refractory Tumor
  • Radiotherapy
  • +4 more
  • Suzhou, China
    The Second Affiliated Hospital of SchoowUniversity
Sep 14, 2023

Severe Aplastic Anemia, Single Lineage Cytopenias, T-LGL, Hypoplastic MDS Trial run by the National Heart, Lung, and Blood

Not yet recruiting
  • Severe Aplastic Anemia
  • +2 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Aug 23, 2023

Gastrointestinal Tumor Trial in Hangzhou (Water-filtered infrared A radiation whole-body hyperthermia (HECKEL 3000MT-4T,

Completed
  • Gastrointestinal Tumor
  • Water-filtered infrared A radiation whole-body hyperthermia (HECKEL 3000MT-4T, Germany)
  • tislelizumab (BeiGene, China) combined with PD-1 inhibitor
  • Hangzhou, China
    Zhejiang Hospital
Sep 1, 2023

Breast Cancer, Ovarian Cancer, Pancreas Cancer Trial (TNG348, Olaparib)

Not yet recruiting
  • Breast Cancer
  • +7 more
  • (no location specified)
Sep 26, 2023

Advanced Solid Tumor Trial in Beijing (Inosine 0.2g orally 3 times/day, PD-1/PD-L1 inhibitor ,chemo/targeting)

Completed
  • Advanced Solid Tumor
  • Inosine 0.2g orally 3 times/day
  • PD-1/PD-L1 inhibitor ,chemotherapy/targeting
  • Beijing, Beijing, China
    Qin li
Mar 30, 2023

Cancer, Cancer Metastatic, BRAF V600E Trial in Indianapolis (Abemaciclib, LY3214996)

Recruiting
  • Cancer
  • +6 more
  • Indianapolis, Indiana
    Indiana University Hospital / IU Simon Cancer Center
Jan 12, 2023

Head Neck Cancer, Intratumoral Injection Trial in Chicago (RiMO-301)

Recruiting
  • Head Neck Cancer
  • Intratumoral Injection
  • Chicago, Illinois
    University of Illinois at Chicago
Apr 28, 2023

Acute Myeloid Leukemia (AML) Trial in Birmingham, San Francisco, New York (ZN-d5 ZN-c3, ZN-c3)

Recruiting
  • Acute Myeloid Leukemia (AML)
  • Birmingham, Alabama
  • +2 more
Jan 3, 2023

Development ofEORTC Immune Checkpoint Inhibitor-specific Quality

Recruiting
  • Cancer
  • +2 more
    • Paris, France
      Institut Curie
    Nov 2, 2022

    HLA-A2 Positive Cells Present, Refractory Melanoma Trial in Buffalo (Alpha-type-1 Polarized Dendritic Cells, Celecoxib, PD-1

    Recruiting
    • HLA-A2 Positive Cells Present
    • Refractory Melanoma
    • Alpha-type-1 Polarized Dendritic Cells
    • +5 more
    • Buffalo, New York
      Roswell Park Cancer Institute
    Dec 12, 2022

    Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer Trial (Giredestrant, Fulvestrant, Abemaciclib)

    Not yet recruiting
    • Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
    • (no location specified)
    Sep 26, 2023

    Neurofibromatosis 1 (NF1), Plexiform Neurofibromas (PN) Trial run by the NCI (Selumetinib)

    Active, not recruiting
    • Neurofibromatosis 1 (NF1)
    • Plexiform Neurofibromas (PN)
    • Bethesda, Maryland
      National Institutes of Health Clinical Center
    Jan 31, 2023

    Metastatic Breast Cancer, Advanced Breast Cancer, HR-positive Breast Cancer Trial (OP-1250, Ribociclib, Alpelisib)

    Not yet recruiting
    • Metastatic Breast Cancer
    • +3 more
    • (no location specified)
    Aug 18, 2022

    Gut and Tumor Microbiome in Advanced ER-positive and

    Not yet recruiting
    • Breast Cancer
    • Melanoma
    • Observation
    • (no location specified)
    Nov 6, 2023

    NSCLC, Carcinoma Breast Trial in Suzhou (Vinorelbine, Radiotherapy, PD-1/PD-L1 inhibitor)

    Not yet recruiting
    • Carcinoma, Non-Small-Cell Lung
    • Carcinoma Breast
    • Suzhou, China
      Second Affiliated Hospital of Soochow University
    Oct 29, 2022